2026 Headache Medicine Reading List

Reading List

Please click below to access the 2026 Headache Medicine reading list.

2026 Headache Medicine Reading List »

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • Describe the clinical presentations of cerebrospinal fluid-related disorders such as IIH and SIH
  • Discuss the emerging use of PACAP inhibitors as potential migraine preventive agents 
  • Discuss the evaluation and management of less common non-migraine conditions, such as nasal and paranasal sinus-related headache, as well as cough, exertional, and sex headache
  • Apply new evidence when making decisions about prescribing triptans during pregnancy
  • Discuss preventive therapies for pediatric migraine

Core Competencies

This UCNS C-cert activity covers the following core competencies:
  • Medical Knowledge
  • Patient Care
  • Practice-Based Learning and Improvement

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

2026 C-cert Activity Planner (Certification Council) Disclosures
All relevant financial relationships have been mitigated.

Headache Medicine Certification Examination Committee Contributors

Stephanie J. Nahas, MD, MSEd, Chair, Thomas Jefferson University/Jefferson Headache Center 
Disclosures: Received honoraria for consulting from AbbVie, Amneal (ended June 2024), Axsome (ended May 2024), Bausch Health (ended July 2025), Eli Lilly (ended November 2024), Lundbeck (ended October 2023), Pfizer, and Tonix (ended November 2023). Received honoraria for work in education or publishing from American Academy of Neurology, American Headache Society, Diamond Headache Clinic Research and Educational Foundation, MedLink Neurology, Springer, WebMD/Medscape, and Wolters-Kluwer. 

Teshamae S. Monteith, MD, Vice Chair, University of Miami 
Disclosures: Received compensation for Advisory: Lundbeck, Axsome, Abbvie, Pfizer, and Teva. Received compensation for consulting for Merz. Received compensation from Continuum (associate editor, audio), Cephalalgia/Cephalalgia Reports (associate editor), New England Journal of Medicine Journal Watch/Clinician (deputy editor), and Neurology Minute (Deputy Editor). Unpaid positions: American Migraine Foundation (board of directors), Florida Society of Neurology (board of directors), and International Headache Society (board of directors). Research support paid to institution: role as site PI for studies led by Abbvie, Eli Lilly, Ipsen. Recipient of educational grant: from Abbvie (paid to institution); received personal fees from Medscape, Massachusetts Medical Society, American Headache Society, and American Academy of Neurology/American Academy of Neurology Institute. Unpaid co-author for publications sponsored by Abbvie, Pfizer, and Theranica. 

Moises Dominguez, MD, Weill Cornell Medicine 
Disclosures: Nothing to disclose. 

Marshall C. Freeman, MD, Headache Wellness Center 
Disclosures: Received research support as Principal Investigator: AbbVie, Biohaven, Ipsen, Kallyope, Lundbeck, and Pfizer. Received compensation as guest speaker, Southern Headache Society. 

P. Christopher H. Gottschalk, MD, Yale Neurology – Headache Division 
Disclosures: Received consulting compensation from Lundbeck, Abbvie, Tonix, Pfizer, and Theranica. Received scientific advisory board compensation from Impel, Satsuma, Vectura Fertin. Received compensation as associate editor, Headache (AHS journal). Received research support from Rehaler--Co-PI, device trial; Ipsen--Co-PI. Serves as immediate past president, AHDA (Alliance for Headache disorders advocacy). 

Christopher B. Oakley, MD, Johns Hopkins University – Department of Child Neurology 
Disclosures: Received compensation as an expert witness in a legal case involving Botox and Allergan. Received royalties for a published book on pediatric headache. 

Nina Riggins, MD, Headache Centers of Excellence VA Healthcare 
Disclosures: Received compensation as Advisory Board Member for NeurologyLive, Lundbeck, Amneal, and Teva. Received compensation as guest editor NeurologyLive. Non compensated, serving on the Board "Miles for Migraine." Principal investigator (PI) Eli Lilly, Theranica clinical trials. Uncompensated work as PI on Research Device from Dolor Technology and TheraSpecs. Participated in educational project, not compensated, with Pfizer. 

Hossain Ansari, MD, Kaizen Brain Center 
Disclosures: Received compensation for serving on Advisory Board from Lundbeck Pharmaceutical and AbbVie. Received compensation for serving on speaker’s bureau from AbbVie pharmaceutical and Scilex Holdings, Inc. 

Seniha Ozudogru, MD, University of Pennsylvania 
Disclosures: Nothing to disclose. 

Carrie E. Robertson, MD, Mayo Clinic - Rochester 
Disclosures: Received compensation as a consultant for AbbVie. Received compensation from LinPharma advisory board. Received compensation as associate editor for UpToDate. Received research support from Pfizer (current) and Lundbeck (through late 2023). 

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326